Trial intelligence / Profile preview

Rosuvastatin in Dilated Cardiomyopathy

NCT00505154Phase 3

Key facts

Status: Completed
Start: Jul 2007
Primary completion: Jul 2013
Countries: 1
Sponsor: Oslo University Hospital
Modality: Orthosteric Ligands

Drugs: rosuvastatin
Conditions: dilated cardiomyopathy (DCM)

Overview

Phase 3, randomised, double-blind trial in dilated cardiomyopathy (DCM) comparing Rosuvastatin with Placebo (2 arms). Primary endpoints: Left Ventricular Ejection Fraction at 6 months, Left Ventricular End Systolic Volume at 6 months and 1 more. Started Jul 2007; status: completed.

Design

2 arms

Study design: RandomizedDouble-blind

Rosuvastatin
Rosuvastatin 10 mg tablets od
Placebo
Placebo tablets

Endpoints

Primary

Left Ventricular Ejection Fraction6 months
Left Ventricular End Systolic Volume6 months
Left Ventricular End Diastolic Volume6 months

Secondary

B-type Natriuretic Peptide6 months
Immunological variables6 months

Beyond the preview

Go deeper on NCT00505154.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00505154.